Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of combined ATG （antithymocyte globulin ） regimen for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborators: 309th Hospital of Chinese People's Liberation Army; Beijing Naval General Hospital; Space Center Hospital, Peking University
• Treatments: Methotrexate; Mycophenolate mofetil; Mycophenolic Acid; Thymoglobulin

Criteria

Inclusion Criteria:

1. acute myeloid leukemia (AML) in CR1 (complete remission 1) or CR2 (complete remission 2) phase regardless of cytogenetics;

2. CML CP(chronic myelogenous leukemia , chronic phase); NHL (non-Hodgkin's lymphoma )

3. MDS-RAEB(myelodysplastic syndrome -refractory anemia with excess blasts ).

4. All patients should aged 40 to 70 years

5. Have matched sibling donor.

6. Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases .

Exclusion Criteria:

1. Patients aged less than 40 years old ;

2. Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or cardiac diseases;

3. AML patients with t (15;17);